Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects

Vaccine

Volumn 24, Issue 20, 2006, Pages 4343-4353

  Firbas, Christa ^a   Jilma, Bernd ^a   Tauber, Erich ^b   Buerger, Vera ^b   Jelovcan, Sandra ^b   Lingnau, Karen ^b   Buschle, Michael ^b   Frisch, Jürgen ^b   Klade, Christoph S ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INTERCELL AG   (Austria)

Author keywords

Hepatitis C; Human; Peptide vaccine; Randomized controlled trial

Indexed keywords

EPITOPE; GAMMA INTERFERON; HEPATITIS C VACCINE; HLA A2 ANTIGEN; IC 41; IMMUNOLOGICAL ADJUVANT; PLACEBO; POLYARGININE; SODIUM CHLORIDE; TETRAMER; THYMIDINE; VIRUS PROTEIN;

ADULT; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFLUENZA; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; LYMPHADENOPATHY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; TH1 CELL; VACCINATION; VACCINATION REACTION;

ADOLESCENT; ADULT; HEPATITIS C; HUMANS; INTERFERON TYPE II; MIDDLE AGED; PLACEBOS; REFERENCE VALUES; SINGLE-BLIND METHOD; T-LYMPHOCYTES; VIRAL VACCINES;

EID: 33646144429     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.009     Document Type: Article

References (64)

1. Alter M.J. Epidemiology of Hepatitis C. Hepatology 26 3 Suppl. 1 (1997) 62S-65S
2. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
3. Houghton M., Weiner A., Han J., Kuo G., and Choo Q.L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 14 2 (1991) 381-388
4. Lohmann V., Koch J.O., and Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J Hepatol 24 2 Suppl. (1996) 11-19
5. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., et al. Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 28 6 (1998) 939-944
6. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 5 Suppl. 1 (2002) S21-S29
7. Shoukry N.H., Cawthon A.G., and Walker C.M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 58 (2004) 391-424
8. + T lymphocytes in acute and chronic hepatitis C. J Mol Med 74 10 (1996) 583-588
9. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 3 (1996) 706-714
10. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
11. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117 4 (1999) 933-941
12. Lamonaca V., Missale G., Urbani S., Pilli M., Boni C., Mori C., et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 30 4 (1999) 1088-1098
13. + T cells with viral clearance in acute hepatitis C. J Infect Dis 181 (2000) 1528-1536
14. Lechner F., Wong D.K.H., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with Hepatitis C virus. J Exp Med 191 (2000) 1499-1512
15. + T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30 9 (2000) 2479-2487
16. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 5645 (2003) 659-662
17. + memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 77 8 (2003) 4781-4793
18. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42 1 (2005) 104-112
19. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 5 (2000) 578-582
20. Lauer G.M., Ouchi K., Chung R.T., Nguyen T.N., Day C.L., Purkis D.R., et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76 12 (2002) 6104-6113
21. + T-helper-cell responses in resolved hepatitis C virus infection. J Virol 76 24 (2002) 12584-12595
22. + T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37 3 (2003) 577-589 [Erratum in: Hepatology 2003;37(4):956]
23. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127 3 (2004) 924-936
24. + T lymphocytes after infection with hepatitis C virus. J Virol 75 12 (2001) 5550-5558
25. + T cells in chronic hepatitis C virus infection. J Immunol 169 6 (2002) 3447-3458
26. + T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 201 11 (2005) 1709-1714
27. Chang K.M., Rehermann B., McHutchison J.G., Pasquinelli C., Southwood S., Sette A., et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100 9 (1997) 2376-2385
28. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15 6 (2001) 883-895
29. Seifert U., Liermann H., Racanelli V., Halenius A., Wiese M., Wedemeyer H., et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 114 2 (2004) 250-259
30. Timm J., Lauer G.M., Kavanagh D.G., Sheridan I., Kim A.Y., Lucas M., et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200 12 (2004) 1593-1604
31. Kimura Y., Gushima T., Rawale S., Kaumaya P., and Walker C.M. Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. J Virol 79 8 (2005) 4870-4876
32. Tester I., Smyk-Pearson S., Wang P., Wertheimer A., Yao E., Lewinsohn D.M., et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 201 11 (2005) 1725-1731
33. Cox A.L., Mosbruger T., Mao Q., Liu Z., Wang X.H., Yang H.C., et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201 11 (2005) 1741-1752
34. Kanto T., Hayashi N., Takehara T., Tatsumi T., Kuzushita N., Ito A., et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 162 9 (1999) 5584-5591
35. Bain C., Fatmi A., Zoulim F., Zarski J.P., Trepo C., and Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120 2 (2001) 512-524
36. Kanto T., Inoue M., Miyatake H., Sato A., Sakakibara M., Yakushijin T., et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 190 11 (2004) 1919-1926
37. Piccioli D., Tavarini S., Nuti S., Colombatto P., Brunetto M., Bonino F., et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 42 1 (2005) 61-67
38. Longman R.S., Talal A.H., Jacobson I.M., Rice C.M., and Albert M.L. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis 192 3 (2005) 497-503
39. Sugimoto K., Ikeda F., Stadanlick J., Nunes F.A., Alter H.J., and Chang K.M. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38 6 (2003) 1437-1448
40. + T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur J Immunol 34 2 (2004) 427-437
41. + T cell differentiation in acute hepatitis C virus infection: the role of the virus. Eur J Immunol 34 2 (2004) 438-446
42. Cabrera R., Tu Z., Xu Y., Firpi R.J., Rosen H.R., Liu C., et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 5 (2004) 1062-1071
43. + T cells during persistent hepatitis C virus infection. J Virol 79 12 (2005) 7852-7859
44. + T cells during chronic hepatitis C virus infection. J Virol 79 12 (2005) 7860-7867
45. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 91 16 (1994) 7792-7796
46. Prince A.M. Challenges for development of hepatitis C virus vaccines. FEMS Microbiol Rev 14 3 (1994) 273-277
47. Brechot C. Hepatitis C virus: molecular biology and genetic variability. Dig Dis Sci 41 12 Suppl. (1996) 6S-21S
48. Bukh J., Miller R.H., and Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15 1 (1995) 41-63
49. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93 26 (1996) 15394-15399
50. Buschle M., Schmidt W., Zauner W., Mechtler K., Trska B., Kirlappos H., et al. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc Natl Acad Sci USA 94 7 (1997) 3256-3261
51. Schmidt W., Buschle M., Zauner W., Kirlappos H., Mechtler K., Trska B., et al. Cell-free tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci USA 94 7 (1997) 3262-3267
52. Mattner F., Fleitmann J.K., Lingnau K., Schmidt W., Egyed A., Fritz J., et al. Vaccination with poly-l-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res 62 5 (2002) 1477-1480
53. Luhrs P., Schmidt W., Kutil R., Buschle M., Wagner S.N., Stingl G., et al. Induction of specific immune responses by polycation-based vaccines. J Immunol 169 9 (2002) 5217-5226
54. Lingnau K., Egyed A., Schellack C., Mattner F., Buschle M., and Schmidt W. Poly-l-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20 29-30 (2002) 3498-3508
55. Gjertson D.W., and Terasaki P.L. HLA 1998 (1998), American Society for Histocompatibility and Immunogenetics, Lenexa, KS
56. Keilholz U., Weber J., Finke J.H., Gabrilovich D.I., Kast W.M., Disis M.L., et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25 2 (2002) 97-138
57. + memory T cells. J Exp Med 186 6 (1997) 859-865
58. Rodman T.C., Pruslin F.H., Chauhan Y., To S.E., and Winston R. Protamine-reactive natural IgM antibodies in human sera. Characterization of the epitope demonstrates specificity of antigenic recognition; occurrence indicates obscurity of origin and function. J Exp Med 167 3 (1988) 1228-1246
59. Inchauspe G. DNA vaccine strategies for hepatitis C. J Hepatol 30 2 (1999) 339-346
60. Hunziker I.P., Zurbriggen R., Glueck R., Engler O.B., Reichen J., Dai W.J., et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol Immunol 38 6 (2001) 475-484
61. Forns X., Bukh J., and Purcell R.H. The challenge of developing a vaccine against hepatitis C virus. J Hepatol 37 5 (2002) 684-695
62. Leroux-Roels G., Depla E., Hulstaert F., Tobback L., Dincq S., Desmet J., et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22 23-24 (2004) 3080-3086
63. Nevens F., Roskams T., Van Vlierberghe H., Horsmans Y., Sprengers D., Elewaut A., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 5 (2003) 1289-1296
64. Brinkman J.A., Fausch S.C., Weber J.S., and Kast W.M. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 4 2 (2004) 181-198